PAVmed PAVM
NASDAQ PAVM
$1.67 +0.09 (+6.03%)
As of: Nov 9, 2026 · 11:37 AM EST

PAVmed (PAVM) Gains (Losses) on Sale of Assets & Investments (2023 - 2026)

Updated

PAVmed (PAVM) recorded Non Operating Investment Income of -$2.5 million in Q2 2026, compared with -$10.64 million a year earlier.

Analysis

PAVmed (PAVM) Gains (Losses) on Sale of Assets & Investments (2023 - 2026) Analysis & Trends

On a TTM basis, PAVmed's Non Operating Investment Income came in at -$15.03 million as of Jun 30, 2026; for FY2025, it was $8.48 million, down 88.3% from FY2024.

  • Across earlier years, Non Operating Investment Income came in at $72.29 million in FY2024 and $1 million in FY2023.
  • Quarterly Non Operating Investment Income has ranged from -$10.64 million in Q2 2025 to $72.29 million in Q3 2024 over the past five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gains on Sales (Qtr)
1 Thermo Fisher Scientific 262.61 Bn 239.12 Bn 5.13 Bn -
2 Abbott Laboratories 190.72 Bn 164.59 Bn 7.39 Bn -
3 Danaher 164.10 Bn 143.75 Bn 3.84 Bn -
4 Intuitive Surgical 160.78 Bn 141.07 Bn 2.08 Bn -
5 Medtronic 131.52 Bn 96.77 Bn 6.34 Bn -
6 Stryker 125.31 Bn 111.50 Bn 4.25 Bn -
7 Boston Scientific 63.61 Bn 59.04 Bn 3.43 Bn -
8 Edwards Lifesciences 60.05 Bn 43.26 Bn 1.35 Bn -
9 Becton Dickinson 59.01 Bn 56.16 Bn 2.32 Bn -
10 PAVmed 10.47 Mn -4.42 Mn -89,000.00 -2.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -2.50 Mn
Dec 31, 2025 2.50 Mn
Sep 30, 2025 -4.38 Mn
Jun 30, 2025 -10.64 Mn
Mar 31, 2025 21.00 Mn
Sep 30, 2024 72.29 Mn
Mar 31, 2023 1.00 Mn
API Access

PAVmed Gains (Losses) on Sale of Assets & Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=PAVM&period=max&api_key=YOUR_API_KEY